Helicobacter Pylori Infection disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HLC007 MIFTS: 59	Helicobacter Pylori Infection Categories: Gastrointestinal diseases, Genetic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Helicobacter Pylori Infection

MalaCards integrated aliases for Helicobacter Pylori Infection:

Name: Helicobacter Pylori Infection ⁵⁶ ⁷¹

Helicobacter Pylori Infection, Susceptibility to ⁵⁶ ²⁹ ⁶ ³⁹

H. Pylori Infection, Susceptibility to ⁵⁶ ¹³

Helicobacter Pylori Infections ⁴²

H. Pylori Infection ⁵⁶

Characteristics:

OMIM:

⁵⁶

Inheritance:
not determined

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM ⁵⁶ 600263

MedGen ⁴¹ C1838332

UMLS ⁷¹ C0850666

Sources

Summaries for Helicobacter Pylori Infection

MedlinePlus : ⁴² Helicobacter pylori (H. pylori) is a type of bacteria that causes infection in the stomach. It is the main cause of peptic ulcers, and it can also cause gastritis and stomach cancer. About 30 to 40 percent of people in the United States get an H. pylori infection. Most people get it as a child. H. pylori usually does not cause symptoms. But it can break down the inner protective coating in some people's stomachs and cause inflammation. This can lead to gastritis or a peptic ulcer. Researchers aren't sure how H. pylori spreads. They think that it may spread by unclean food and water, or through contact with an infected person's saliva and other body fluids. A peptic ulcer causes a dull or burning pain in your stomach, especially when you have an empty stomach. It lasts for minutes to hours, and it may come and go for several days or weeks. It may also cause other symptoms, such as bloating, nausea, and weight loss. If you have the symptoms of a peptic ulcer, your health care provider will check to see whether you have H. pylori. There are blood, breath, and stool tests to check for H. pylori. In some cases, you may need an upper endoscopy, often with a biopsy. If you do have a peptic ulcer, the treatment is with a combination of antibiotics and acid-reducing medicines. You will need to be tested again after treatment to make sure the infection is gone. There is no vaccine for H. pylori. Since H. pylori might spread through unclean food and water, you might be able to prevent it if you Wash your hands after using the bathroom and before eating Eat properly prepared food Drink water from a clean, safe source NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Helicobacter Pylori Infection, also known as helicobacter pylori infection, susceptibility to, is related to peptic ulcer disease and atrophic gastritis, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Helicobacter Pylori Infection is IFNGR1 (Interferon Gamma Receptor 1), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Acetylcysteine and Potassium citrate have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and colon, and related phenotypes are helicobacter pylori infection and Synthetic lethal with MLN4924 (a NAE inhibitor)

OMIM : ⁵⁶ Helicobacter pylori is a microaerophilic, gram-negative bacterium that colonizes the gastric mucosa of approximately 50% of the world's population, and is a primary pathogenic factor in benign and malignant gastroduodenal disease (Warren and Marshall, 1983; Blaser and Parsonnet, 1994). Tomb et al. (1997) reported the complete sequence of the circular genome of H. pylori. The 1,667,867-bp genome contains 1,590 predicted coding sequences (genes). Sequence analysis of these genes indicated that the organism has systems for motility, for scavenging iron, and for DNA restriction and modification. Its survival in acid conditions depends, in part, on its ability to establish a positive inside-membrane potential in low pH. (600263)

Sources

Related Diseases for Helicobacter Pylori Infection

Diseases related to Helicobacter Pylori Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 610)

#	Related Disease	Score	Top Affiliating Genes
1	peptic ulcer disease	32.8	S100A8 NFKB1 IL1B GAST CYP2C19 CXCL8
2	atrophic gastritis	31.9	S100A8 MUC6 IL1B GAST CXCL8
3	gastric ulcer	31.9	S100A8 IL1B GAST CYP2C19 CXCL8
4	duodenal ulcer	31.7	S100A8 IL1B GAST CYP2C19 CXCL8 CXCL1
5	microinvasive gastric cancer	31.7	S100A8 MUC6 GAST
6	gastroesophageal reflux	31.6	S100A8 IL1B GAST CYP2C19 CXCL8
7	autoimmune gastritis	31.4	IL1B GAST EGFR
8	gastroduodenitis	31.3	S100A8 GAST
9	peptic esophagitis	31.3	S100A8 IL1B GAST CYP2C19 CXCL8
10	diarrhea	31.3	IL1B GAST EGFR CXCL8
11	chlamydia	31.2	NOD1 IL1B CXCL8
12	duodenum disease	31.2	S100A8 MUC6 GAST
13	peptic ulcer perforation	31.1	S100A8 GAST
14	proteasome-associated autoinflammatory syndrome 1	31.0	IL1B CXCL8 CCL5
15	crohn's disease	31.0	S100A8 NOD1 IL1B CXCL8
16	gastritis	31.0	S100A8 NOD1 MUC6 IL1B GAST CYP2C19
17	esophagitis	30.8	IL1B GAST EGFR CYP2C19 CXCL8 CCL5
18	cholecystitis	30.8	S100A8 MUC6 EGFR
19	mycobacterium fortuitum	30.7	IFNGR1 CXCL8
20	prostatitis	30.7	IL1B CXCL8 CASP3
21	shigellosis	30.7	NOD1 IL1B CXCL8
22	non-alcoholic fatty liver disease	30.6	JUN IL1B CXCL8 CASP3
23	idiopathic neutropenia	30.4	IL1B CCL5 CASP3
24	appendicitis	30.4	S100A8 IL1B CXCL8
25	tonsillitis	30.3	IL1B CXCL8 CXCL1 CASP3
26	salmonellosis	30.3	JUN IL1B IFNGR1
27	gastroesophageal junction adenocarcinoma	30.2	PAK1 IL1B EGFR
28	gastric cancer	30.2	S100A8 PTPN11 PAK1 MUC6 MET JUN
29	gingivitis	30.0	IL1B CXCL8 CCL5
30	neuritis	30.0	IL1B CXCL8 CCL5
31	gastric adenocarcinoma	29.8	S100A8 NFKB1 MET JUN IL1B GAST
32	monocytic leukemia	29.7	JUN IL1B CXCL8 CASP3
33	pertussis	29.6	JUN IL1B CXCL8 CCL5
34	cystic fibrosis	29.3	S100A8 MUC6 JUN IL1B CXCL8
35	eye disease	29.1	JUN IL1B CXCL8 CCL5 CASP3
36	lung disease	29.1	S100A8 MET IL1B IFNGR1 EGFR CXCL8
37	cytomegalovirus infection	29.1	NFKB1 IL1B CXCL8 CHUK CCL5 CASP3
38	arthritis	29.0	JUN IL1B CXCL8 CXCL1 CCL5
39	rheumatoid arthritis	28.8	NFKBIA JUN IL1B CXCL8 CXCL1 CCL5
40	inflammatory bowel disease	28.7	S100A8 NOD1 NFKB1 JUN IL1B IFNGR1
41	t-cell leukemia	28.7	NFKBIA NFKB1 JUN CHUK CASP3
42	pancreatic adenocarcinoma	28.7	MUC6 MET JUN GAST EGFR CXCL8
43	squamous cell carcinoma, head and neck	28.7	NFKBIA MET JUN EGFR CXCL8 CASP3
44	colon adenocarcinoma	28.7	JUN EGFR CXCL8 CASP3
45	pancreatic cancer	28.3	NFKBIA NFKB1 MUC6 MET JUN GAST
46	gastric cancer, hereditary diffuse	11.9
47	gastrointestinal ulceration, recurrent, with dysfunctional platelets	11.1
48	iron metabolism disease	11.0
49	lymphoma, mucosa-associated lymphoid type	11.0
50	deficiency anemia	10.9

Graphical network of the top 20 diseases related to Helicobacter Pylori Infection:

Sources

Symptoms & Phenotypes for Helicobacter Pylori Infection

Human phenotypes related to Helicobacter Pylori Infection:

³¹

#	Description	HPO Frequency	HPO Source Accession
1	helicobacter pylori infection ³¹		HP:0005202

Symptoms via clinical synopsis from OMIM:

⁵⁶

G I:
helicobacter pylori infection susceptibility

Clinical features from OMIM:

600263

UMLS symptoms related to Helicobacter Pylori Infection:

nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.83	CASP3 CHUK CXCL8 IL1B JUN NFKB1
2	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.83	CASP3 CHUK CXCL8 IL1B JUN NFKB1

MGI Mouse Phenotypes related to Helicobacter Pylori Infection:

⁴⁵ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	10.28	ADAM10 CASP3 CCL5 CHUK EGFR GAST
2	hematopoietic system	MP:0005397	10.27	ADAM10 CASP3 CCL5 CHUK EGFR IFNGR1
3	cellular	MP:0005384	10.26	ADAM10 CASP3 CHUK EGFR IFNGR1 JUN
4	homeostasis/metabolism	MP:0005376	10.25	ADAM10 CASP3 CHUK EGFR GAST IFNGR1
5	cardiovascular system	MP:0005385	10.24	ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B
6	endocrine/exocrine gland	MP:0005379	10.22	ADAM10 CASP3 CHUK EGFR GAST IFNGR1
7	digestive/alimentary	MP:0005381	10.15	ADAM10 CASP3 CHUK EGFR GAST IFNGR1
8	mortality/aging	MP:0010768	10.13	ADAM10 CASP3 CHUK EGFR GAST IFNGR1
9	craniofacial	MP:0005382	10.11	ADAM10 CASP3 CHUK EGFR IL1B MET
10	integument	MP:0010771	10.07	ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B
11	nervous system	MP:0003631	9.9	ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B
12	neoplasm	MP:0002006	9.8	CHUK EGFR GAST IFNGR1 IL1B MET
13	respiratory system	MP:0005388	9.56	CASP3 CHUK EGFR JUN MET NFKB1
14	skeleton	MP:0005390	9.32	ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B

Sources

Drugs & Therapeutics for Helicobacter Pylori Infection

Drugs for Helicobacter Pylori Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Acetylcysteine

Approved, Investigational

Phase 4

616-91-1

12035

Potassium citrate

Approved, Investigational, Vet_approved

Phase 4

Histamine

Approved, Investigational

Phase 4

51-45-6

774

Titanium dioxide

Approved

Phase 4

13463-67-7

Famotidine

Approved

Phase 4

76824-35-6

3325

Coal tar

Approved

Phase 4

8007-45-2

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4

93-14-1

3516

Doxycycline

Approved, Investigational, Vet_approved

Phase 4

564-25-0

54671203

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

Rifabutin

Approved, Investigational

Phase 4

72559-06-9

6323490 46783538

Loperamide

Approved

Phase 4

53179-11-6

3955

Bismuth subsalicylate

Approved, Vet_approved

Phase 4

14882-18-9

53629521

Tinidazole

Approved, Investigational

Phase 4

19387-91-8

5479

Azithromycin

Approved

Phase 4

83905-01-5

55185 447043

Levofloxacin

Approved, Investigational

Phase 4

100986-85-4

149096

Ofloxacin

Approved

Phase 4

82419-36-1

4583

Rabeprazole

Approved, Investigational

Phase 4

117976-89-3

5029

Clavulanate

Approved, Vet_approved

Phase 4

58001-44-8

5280980

Coenzyme Q10

Approved, Investigational, Nutraceutical

Phase 4

303-98-0

5281915

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Calcium

Approved, Nutraceutical

Phase 4

7440-70-2

271

Glycine

Approved, Nutraceutical, Vet_approved

Phase 4

56-40-6

750

Sulforaphane

Investigational

Phase 4

142825-10-3, 4478-93-7

5350

Furazolidone

Experimental, Vet_approved

Phase 4

67-45-8

3435 5323714

N-monoacetylcystine

Phase 4

Free Radical Scavengers

Phase 4

Antioxidants

Phase 4

Antiviral Agents

Phase 4

Antidotes

Phase 4

Natriuretic Agents

Phase 4

Respiratory System Agents

Phase 4

Expectorants

Phase 4

diuretics

Phase 4

Histamine Antagonists

Phase 4

Histamine H2 Antagonists

Phase 4

Histamine Phosphate

Phase 4

51-74-1

65513

Acidophilus

Phase 4

Hemostatics

Phase 4

Chlorpheniramine, phenylpropanolamine drug combination

Phase 4

Chelating Agents

Phase 4

Citrate

Phase 4

Anticoagulants

Phase 4

Calcium, Dietary

Phase 4

Neurotransmitter Agents

Phase 4

Bifidobacterium

Phase 4

Antimalarials

Phase 4

Trace Elements

Phase 4

Micronutrients

Phase 4

Nutrients

Phase 4

Bile Acids and Salts

Phase 4

Interventional clinical trials:

(show top 50) (show all 385)

#	Name	Status	NCT ID	Phase	Drugs
1	Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication	Unknown status	NCT02934152	Phase 4	H pylori eradication
2	Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial	Unknown status	NCT02635191	Phase 4	Tailored Group;Standard group
3	Comparison of the Efficacy of Sequential Therapy and Bismuth Quadruple Therapy in the First Line and Second Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial	Unknown status	NCT03156855	Phase 4	14-day sequential therapy;Bismuth quadruple therapy
4	Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection	Unknown status	NCT02934048	Phase 4
5	Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial	Unknown status	NCT01906879	Phase 4	triple, quadruple, non-bismuth quadruple therapy
6	Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study	Unknown status	NCT03130452	Phase 4	Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
7	Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial	Unknown status	NCT02249546	Phase 4	N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
8	Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer	Unknown status	NCT00155389	Phase 4	Helicobacter pylori eradication
9	Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy	Unknown status	NCT01265069	Phase 4	high dose dual therapy;concomitant therapy
10	Helicobacter Pylori Eradication Using a Bismuth Quadruple Therapy Among Asymptomatically Infected Adults in El Paso, Texas: A Pilot Study.	Unknown status	NCT01335334	Phase 4	bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole
11	Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance	Unknown status	NCT01464060	Phase 4	PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
12	Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial	Unknown status	NCT03134378	Phase 4	Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
13	Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea	Unknown status	NCT02108184	Phase 4	Sequential therapy 10 days;Sequential therapy 14 days;Concomitant therapy 10 days;Concomitant therapy 14 days
14	Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole	Unknown status	NCT02552641	Phase 4	Esomeprazole;Amoxicillin;Clarythromycin
15	Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial	Unknown status	NCT01607918	Phase 4	D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole);D1-D14: (lansoprazole + clarithromycin + amoxicillin)
16	A Randomized, Double-blind, Placebo-controlled Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice	Unknown status	NCT03150394	Phase 4
17	The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation	Unknown status	NCT01765998	Phase 4	Probiotic;Placebo
18	Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment	Unknown status	NCT03139253	Phase 4	amoxicillin;clarithromycin;tinidazole;levofloxacin;furazolidone;tetracycline;Ilaprazole
19	Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment	Unknown status	NCT02988089	Phase 4	Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
20	Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections	Unknown status	NCT01566643	Phase 4	RA5-RACM7;RA3-RACM7;RA7-RACM7
21	Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy.	Unknown status	NCT01572597	Phase 4	10RAC+acetylcystein;10RAC+metronidazole
22	Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial	Unknown status	NCT01537055	Phase 4	levofloxacin-based sequential therapy;levofloxacin-based triple therapy for 10 days
23	Phase 4 Study of Helicobacter Pylori Eradication Therapy	Unknown status	NCT00990405	Phase 4	Lansoprzole+Amoxicillin+Clarithromycin
24	Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection	Unknown status	NCT01725906	Phase 4	empirical therapy;Genotypic resistance guided therapy
25	Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice	Unknown status	NCT01273441	Phase 4	PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
26	The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study	Completed	NCT00885417	Phase 4	Cravit-based sequential therapy
27	Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori	Completed	NCT01573975	Phase 4	5RA-5RCM;5RA-5RCT;10RCA
28	Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection	Completed	NCT02541786	Phase 4	dexlansoprazole based triple therapy;rabeprazole-based triple therapy
29	The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection	Completed	NCT01032655	Phase 4	susceptibility test guided sequential therapy
30	Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan	Completed	NCT01769365	Phase 4	7-day quadruple therapy;10-day sequential therapy;7-day standard triple therapy
31	Canadian North Helicobacter Pylori (CANHelp) Working Group Treatment Trials	Completed	NCT01967329	Phase 4	Standard Triple;Sequential;Quadruple
32	Phase IV Study Comparing the Duration of Sequential Therapy	Completed	NCT01042184	Phase 4	Sequential therapy for 14 days;Sequential therapy for 10 days;Triple therapy for 14 days
33	Intraluminal Therapy for Helicobacter Pylori Infection	Completed	NCT03124420	Phase 4	Lansoprazole;Amoxicillin;Clarithromycin
34	Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for First-line Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study	Completed	NCT02483715	Phase 4	High-dose dual therapy (rabeprazole, amoxicillin);Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
35	Comparison of 14-day Sequential and Hybrid Therapies for H Pylori Infection	Completed	NCT01085786	Phase 4	14-day sequential treatment;14-day hybrid treatment
36	A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection	Completed	NCT02959255	Phase 4	Esomeprazole
37	Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan	Completed	NCT03524833	Phase 4	Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
38	Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan	Completed	NCT03521726	Phase 4	Amoxicillin;Rabeprazole, Amoxicillin
39	Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan	Completed	NCT03516669	Phase 4	Clarithromycin;Amoxicillin, Clarithromycin
40	Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection	Completed	NCT02175927	Phase 4	Lansoprazole;Bismuth Potassium Citrate;Metronidazole;Amoxicillin;Tetracycline
41	Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori	Completed	NCT03108287	Phase 4	RAK therapy;RBAK therapy
42	Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection	Completed	NCT02711176	Phase 4	Nexium;Tinafas;Tavanex;Lanzol;Klacid;Iramox
43	An Interventional, Prospective, Multi-center, Double-blind, Placebo Controlled Postmarketing Study to Evaluate Efficacy and Safety of Normia® Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori	Completed	NCT01969331	Phase 4
44	The Effect of High Dose Citric on PPI (Proton Pump Inhibitors)Induced False Negative H. Pylori UBT Rates	Completed	NCT00825630	Phase 4	Lansoprazole (Lanton);Omeprezole (Losec);Pantoprazole(Controloc);Esomeprazole (Nexium)
45	Levoﬂoxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection	Completed	NCT01742429	Phase 4	Proton pump inhibitor;Bismuth subsalicylate;Metronidazole;Tetracycline;Amoxicillin;Levofloxacin
46	Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial	Completed	NCT04039412	Phase 4	Hybrid regimen;Reverse hybrid regimen;Levofloxacin quadruple regimen
47	Efficacy of High Dose of Amoxicillin And Metronidazole Plus Bismuth For Helicobacter Pylori Treatment In Naive Patients : A Randomized Clinical Trial	Completed	NCT03557437	Phase 4	Esomeprazole;Amoxicillin, Metronidazole;Bismuth Potassium Citrate
48	A Randomized Controlled Trial of Triple Therapy Versus Sequential Therapy Versus Concomitant Therapy as First Line Treatment for Helicobacter Pylori Infection	Completed	NCT02092506	Phase 4	10 day triple therapy;10 day sequential therapy;10 day concomitant therapy
49	Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura	Completed	NCT00467571	Phase 4	lansoprazole, clarithromycin, amoxycillin
50	Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study	Completed	NCT00854451	Phase 4	omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin

Search NIH Clinical Center for Helicobacter Pylori Infection

Sources

Genetic Tests for Helicobacter Pylori Infection

Genetic tests related to Helicobacter Pylori Infection:

#	Genetic test	Affiliating Genes
1	Helicobacter Pylori Infection, Susceptibility to ²⁹	IFNGR1

Sources

Anatomical Context for Helicobacter Pylori Infection

MalaCards organs/tissues related to Helicobacter Pylori Infection:

⁴⁰

Testes, Liver, Colon, T Cells, B Cells, Heart, Kidney

Sources

Publications for Helicobacter Pylori Infection

Articles related to Helicobacter Pylori Infection:

(show top 50) (show all 12386)

#	Title	Authors	PMID	Year
1	Genomewide linkage analysis identifies polymorphism in the human interferon-gamma receptor affecting Helicobacter pylori infection. ⁶¹ ⁵⁶ ⁶	Thye T...Horstmann RD	12516030	2003
2	Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. ⁶¹ ⁵⁶	Kawakubo M...Nakayama J	15310903	2004
3	Transmission of Helicobacter pylori infection. ⁶¹ ⁵⁶	Mendall MA...Northfield TC	7672655	1995
4	Expression of a human alpha-1,3/4-fucosyltransferase in the pit cell lineage of FVB/N mouse stomach results in production of Leb-containing glycoconjugates: a potential transgenic mouse model for studying Helicobacter pylori infection. ⁶¹ ⁵⁶	Falk PG...Gordon JI	7878011	1995
5	Helicobacter pylori infection: genetic and environmental influences. A study of twins. ⁶¹ ⁵⁶	Malaty HM...Graham DY	8185146	1994
6	Seroprevalence of helicobacter pylori infection in couples. ⁶¹ ⁵⁶	Perez-Perez GI...Blaser MJ	2037687	1991
7	Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis. ⁶¹ ⁴²	Liu R...Shao Y	31689846	2019
8	A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. ⁵⁶	Tanikawa C...Matsuda K	22387998	2012
9	A regulatory polymorphism in interferon-gamma receptor 1 promoter is associated with the susceptibility to chronic hepatitis B virus infection. ⁶	Zhou J...Zheng BJ	19488747	2009
10	Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. ⁵⁶	Study Group of Millennium Genome Project for Cancer...Hirohashi S	18488030	2008
11	Helicobacter exploits integrin for type IV secretion and kinase activation. ⁵⁶	Kwok T...Backert S	17943123	2007
12	Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis. ⁶	Cooke GS...Hill AV	16690980	2006
13	Distinguishing human ethnic groups by means of sequences from Helicobacter pylori: lessons from Ladakh. ⁵⁶	Wirth T...Achtman M	15051885	2004
14	Protective immunity against Helicobacter is characterized by a unique transcriptional signature. ⁵⁶	Mueller A...Falkow S	14528007	2003
15	Treatment of Helicobacter gastritis with IL-4 requires somatostatin. ⁵⁶	Zavros Y...Merchant JL	14555768	2003
16	Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. ⁵⁶	Fujikawa A...Noda M	12598897	2003
17	Lewis enzyme (alpha1-3/4 fucosyltransferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population. ⁵⁶	Serpa J...David L	12730721	2003
18	Helicobacter pylori and gastrointestinal tract adenocarcinomas. ⁵⁶	Peek RM...Blaser MJ	11902583	2002
19	Polymorphisms of two fucosyltransferase genes (Lewis and Secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobacter pylori IgG antibody. ⁵⁶	Ikehara Y...Tatematsu M	11535550	2001
20	The complete genome sequence of the gastric pathogen Helicobacter pylori. ⁵⁶	Tomb JF...Venter JC	9252185	1997
21	Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. ⁵⁶	Blaser MJ...Parsonnet J	8040281	1994
22	Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. ⁵⁶	Telford JL...Xiang Z	8163943	1994
23	Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. ⁵⁶	Boren T...Normark S	8018146	1993
24	Purification and characterization of the vacuolating toxin from Helicobacter pylori. ⁵⁶	Cover TL...Blaser MJ	1587837	1992
25	Unidentified curved bacilli on gastric epithelium in active chronic gastritis. ⁵⁶	Warren JR...Marshall B	6134060	1983
26	Comparative study of magnifying narrow-band imaging and conventional white light endoscopy in the diagnosis of Helicobacter pylori status after eradication therapy. ⁴²	Tahara T...Ohmiya N	31725612	2019
27	Helicobacter pylori eradication in dyspepsia: New evidence for symptomatic benefit. ⁴²	Koletzko L...Malfertheiner P	31594649	2019
28	MAEL Cancer-Testis Antigen as a Diagnostic Marker in Primary Stages of Gastric Cancer with Helicobacter pylori Infection. ⁶¹	Abbaszadegan MR...Moghbeli M	30488287	2020
29	Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study. ⁶¹	Kumar S...Goldberg DS	31654635	2020
30	One Step Forward But Room for Improvement in Reducing Risk of Gastric Cancer by Curing Helicobacter pylori Infection. ⁶¹	Howden CW	31730770	2020
31	Application of Helicobacter pylori stool antigen test to survey the updated prevalence of Helicobacter pylori infection in Taiwan. ⁶¹	Chen MJ...Taiwan Gastrointestinal Disease and Helicobacter Consortium	31408909	2020
32	Helicobacter pylori infection leads to KLF4 inactivation in gastric cancer through a TET1-mediated DNA methylation mechanism. ⁶¹	Zhao R...Wang S	32017451	2020
33	Previous Helicobacter pylori infection-induced atrophic gastritis: A distinct disease entity in an understudied population without a history of eradication. ⁶¹	Kishikawa H...Nishida J	31680399	2020
34	The relationship of gastric microbiota and Helicobacter pylori infection in pediatrics population. ⁶¹	Miao R...Wang Z	31762120	2020
35	Risk for Colorectal Neoplasia in Patients With Helicobacter pylori Infection: A Systematic Review and Meta-analysis. ⁶¹	Choi DS...Park CH	32032128	2020
36	Potential Impact of Helicobacter pylori Infection on Reflux Disease Sequence: Illuminating the Gap. ⁶¹	Kountouras J...Doulberis M	31851102	2020
37	Inhibitory Effects of β-Caryophyllene on Helicobacter pylori Infection In Vitro and In Vivo. ⁶¹	Woo HJ...Kim JB	32028744	2020
38	[Helicobacter pylori infection in the HIV + population: a comorbidity to think about]. ⁶¹	Valencia ME...Serrano L	31933346	2020
39	Development of a novel gene signature in patients without Helicobacter pylori infection gastric cancer. ⁶¹	Lv X...He M	31633246	2020
40	Clostridium difficile-associated disease and Helicobacter pylori seroprevalence: A case-control study. ⁶¹	Muhsen K...Cohen D	31721371	2020
41	The clinicopathological characteristics and genetic alterations of mucinous carcinoma of the stomach. ⁶¹	Tseng CH...Shyr YM	32015267	2020
42	Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis. ⁶¹	Papaefthymiou A...Kountouras J	31692137	2020
43	Low Prevalence of Helicobacter pylori-Positive Peptic Ulcers in Private Outpatient Endoscopy Centers in the United States. ⁶¹	Sonnenberg A...Genta RM	31972622	2020
44	Co-expression of Interleukin-17A molecular adjuvant and prophylactic Helicobacter pylori genetic vaccine could cause sterile immunity in Treg suppressed mice. ⁶¹	Nemattalab M...Mousavi Niri N	31629103	2020
45	Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. ⁶¹	Puig I...Spanish Gastroenterological Association Gastroduodenal Diseases Study Group	31787375	2020
46	Preoperative Endoscopic Findings in Veterans Undergoing Bariatric Surgery: Prevalence and Predictors of Barrett's Esophagus. ⁶¹	Ozeki KA...Eisenberg D	31713148	2020
47	Performance of multiplex serology in discriminating active vs past Helicobacter pylori infection in a primarily African American population in the southeastern United States. ⁶¹	Butt J...Epplein M	31746104	2020
48	Prevalence of Helicobacter pylori infection rate in heterotopic gastric mucosa in histological analysis of duodenal specimens from patients with duodenal ulcer. ⁶¹	Noguchi H...Nakayama T	31264199	2020
49	10-Day Versus 14-Day Quadruple Concomitant Nonbismuth Therapy for the Treatment of Helicobacter pylori Infection: Results From a Randomized Prospective Study in a High Clarithromycin Resistance Country. ⁶¹	Apostolopoulos P...Alexandrakis G	32028286	2020
50	Statins Were Associated with a Reduced Gastric Cancer Risk in Patients with Eradicated Helicobacter Pylori Infection: A Territory-Wide Propensity Score Matched Study. ⁶¹	Cheung KS...Leung WK	31792089	2020

Sources

Genes for Helicobacter Pylori Infection

Genes related to Helicobacter Pylori Infection (1 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	IFNGR1	Interferon Gamma Receptor 1	Protein Coding	701.73	Molecular basis known ⁵⁶ Genetic Tests ²⁹ Susceptibility factor ⁵⁶ Risk factor ⁶ GeneCards inferred via : Publications Summaries Proteins (show sections)	12516030 19488747 16690980
2	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	17.65	GeneCards inferred via : Publications Pathways & Interactions (show sections)
3	NOD1	Nucleotide Binding Oligomerization Domain Containing 1	Protein Coding	16.41	GeneCards inferred via : Publications Pathways & Interactions (show sections)
4	CASP3	Caspase 3	Protein Coding	16.32	GeneCards inferred via : Publications Pathways & Interactions (show sections)
5	CHUK	Component Of Inhibitor Of Nuclear Factor Kappa B Kinase Complex	Protein Coding	16.08	GeneCards inferred via : Publications Pathways & Interactions (show sections)
6	CXCL1	C-X-C Motif Chemokine Ligand 1	Protein Coding	16.08	GeneCards inferred via : Publications Pathways & Interactions (show sections)
7	EGFR	Epidermal Growth Factor Receptor	Protein Coding	16.08	GeneCards inferred via : Publications Pathways & Interactions (show sections)
8	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	16.08	GeneCards inferred via : Publications Pathways & Interactions (show sections)
9	NFKB1	Nuclear Factor Kappa B Subunit 1	Protein Coding	16.08	GeneCards inferred via : Publications Pathways & Interactions (show sections)
10	NFKBIA	NFKB Inhibitor Alpha	Protein Coding	16.08	GeneCards inferred via : Publications Pathways & Interactions (show sections)
11	PTPN11	Protein Tyrosine Phosphatase Non-Receptor Type 11	Protein Coding	15.93	GeneCards inferred via : Publications Pathways & Interactions (show sections)
12	CCL5	C-C Motif Chemokine Ligand 5	Protein Coding	15.73	GeneCards inferred via : Publications Pathways & Interactions (show sections)
13	JUN	Jun Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	15.73	GeneCards inferred via : Publications Pathways & Interactions (show sections)
14	ADAM10	ADAM Metallopeptidase Domain 10	Protein Coding	15.44	GeneCards inferred via : Publications Pathways & Interactions (show sections)
15	PAK1	P21 (RAC1) Activated Kinase 1	Protein Coding	15.44	GeneCards inferred via : Publications Pathways & Interactions (show sections)
16	IL1B	Interleukin 1 Beta	Protein Coding	8.62	GeneCards inferred via : Publications (show sections)
17	MUC6	Mucin 6, Oligomeric Mucus/Gel-Forming	Protein Coding	8.4	GeneCards inferred via : Publications (show sections)
18	GAST	Gastrin	Protein Coding	8.34	GeneCards inferred via : Publications (show sections)
19	CYP2C19	Cytochrome P450 Family 2 Subfamily C Member 19	Protein Coding	8.3	GeneCards inferred via : Publications (show sections)
20	S100A8	S100 Calcium Binding Protein A8	Protein Coding	8.28	GeneCards inferred via : Publications (show sections)

Sources

Variations for Helicobacter Pylori Infection

ClinVar genetic disease variations for Helicobacter Pylori Infection:

⁶ ‎‎

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	GRCh37 Pos	GRCh38 Pos
1	IFNGR1	IFNGR1, -56C-T	SNV	protective,risk factor	17953

Sources

Expression for Helicobacter Pylori Infection

Search GEO for disease gene expression data for Helicobacter Pylori Infection.

Sources

Pathways for Helicobacter Pylori Infection

Pathways related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 152)

#	Super pathways	Score	Top Affiliating Genes
1	Signaling by GPCR ⁶⁵ Show member pathways GPCR downstream signaling ⁶⁵ Signal Transduction ⁶⁵	14.32	PTPN11 PAK1 NFKBIA NFKB1 MET JUN
2	Innate Immune System ⁶⁵ Show member pathways Immune System ⁶⁵ Neutrophil degranulation ⁶⁵	14.02	S100A8 PTPN11 PAK1 NOD1 NFKBIA NFKB1
3	ERK Signaling ⁶³ Show member pathways ILK Signaling ⁶³ MAPK Signaling ⁶³ Molecular Mechanisms of Cancer ⁶³ Rho Family GTPases ⁶³	13.98	PAK1 NFKBIA NFKB1 MET JUN IL1B
4	PEDF Induced Signaling ⁶³ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶³ Cytokine-cytokine receptor interaction ³⁶ Endothelin-1 Signaling Pathway ⁶³ Glucocorticoid Receptor Signaling ⁶³ IL-6 Pathway ⁶³ MIF Mediated Glucocorticoid Regulation ⁶³ MIF Regulation of Innate Immune Cells ⁶³ NFAT Signaling and Lymphocyte Interactions ⁶³ PGC1Alpha Pathway ⁶³ RAR-Gamma-RXR-Alpha Degradation ⁶³ STAT3 Pathway ⁶³	13.84	NFKBIA NFKB1 MET JUN IL1B IFNGR1
5	HIV Life Cycle ⁶⁵ Show member pathways 2-LTR circle formation ⁶⁵ APOBEC3G mediated resistance to HIV-1 infection ⁶⁵ Assembly Of The HIV Virion ⁶⁵ Binding and entry of HIV virion ⁶⁵ Disease ⁶⁵ Diseases of signal transduction ⁶⁵ Early Phase of HIV Life Cycle ⁶⁵ HIV Infection ⁶⁵ Host Interactions of HIV factors ⁶⁵ Infectious disease ⁶⁵ Integration of provirus ⁶⁵ Late Phase of HIV Life Cycle ⁶⁵	13.83	PTPN11 NFKBIA NFKB1 MUC6 MET JUN
6	TGF-Beta Pathway ⁶³ Show member pathways JAK-STAT Pathway ⁶³ JNK Pathway ⁶³ MAPK Family Pathway ⁶³ Regulation of eIF4 and p70S6K ⁶³ SOCS Pathway ⁶³	13.71	PTPN11 PAK1 NFKBIA NFKB1 MET JUN
7	Akt Signaling ⁶³ Show member pathways p38 Signaling ⁶³ Tec Kinases Signaling ⁶³	13.58	PAK1 NFKB1 MET IL1B EGFR CXCL8
8	Integrin Pathway ⁶³ Show member pathways FAK1 Signaling ⁶³ GnRH Signaling ⁶³ Inhibition of Angiogenesis by TSP1 ⁶³ Transendothelial Migration of Leukocytes ⁶³ UPA-UPAR Pathway ⁶³	13.53	PAK1 NFKB1 JUN EGFR CXCL8 CXCL1
9	Cytokine Signaling in Immune system ⁶⁵ Show member pathways Signaling by Interleukins ⁶⁵	13.47	PTPN11 NOD1 NFKB1 MET IL1B IFNGR1
10	IL-2 Pathway ⁶³ Show member pathways ErbB Family Pathway ⁶³ ErbB2-ErbB3 Heterodimers ⁶³ ErbB4 Pathway ⁶³ Growth Hormone Signaling ⁶³ HMGB1 Pathway ⁶³ IL-4 Pathway ⁶³ LPS Stimulated MAPK Signaling ⁶³ PACAP Signaling ⁶³ PI3K Signaling in B-Lymphocyte ⁶³ Prolactin Signaling ⁶³ Thrombopoietin Pathway ⁶³ TREM1 Pathway ⁶³ UVC-Induced MAPK Signaling ⁶³	13.36	PAK1 NFKBIA NFKB1 JUN IL1B IFNGR1
11	PAK Pathway ⁶³ Show member pathways Antioxidant Action of Vitamin-C ⁶³ Epithelial Adherens Junctions ⁶³	13.34	PTPN11 PAK1 NFKBIA NFKB1 MET JUN
12	Toll-like Receptor Signaling Pathway ¹ ³⁶ Show member pathways Chagas disease (American trypanosomiasis) ³⁶ Hepatitis B ³⁶ Hepatitis C ³⁶ NOD-like Receptor Signaling Pathways ⁶⁴ Regulation of toll-like receptor signaling pathway ¹	13.2	NOD1 NFKBIA NFKB1 JUN IL1B IFNGR1
13	p70S6K Signaling ⁶³ Show member pathways mTOR Pathway ⁶³ Renin-Angiotensin Pathway ⁶³	13.17	PAK1 NFKB1 MET JUN EGFR CHUK
14	fMLP Pathway ⁶³ Show member pathways Alpha-Adrenergic Signaling ⁶³ CCR3 Pathway in Eosinophils ⁶³ CXCR4 Pathway ⁶³ Huntington's Disease Pathway ⁶³ Internalin Pathway ⁶³ Signal transduction Activation of PKC via G-Protein coupled receptor ²² VEGF and S-1P Signaling ⁶³	13.15	PAK1 NFKBIA NFKB1 MET JUN CHUK
15	TNFR1 Pathway ⁶³ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis through Death Receptors ⁶³ Apoptotic Pathways Triggered By HIV1 ⁶³ DR3 Signaling ⁶³ Fas Signaling ⁶³ GITR Pathway ⁶³ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁵ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶³ TRAIL Pathway ⁶³ TWEAK Pathway ⁶³	13.13	PAK1 NFKBIA NFKB1 JUN EGFR CHUK
16	CCR5 Pathway in Macrophages ⁶³ Show member pathways Androgen Signaling ⁶³ Chemokine Signaling ⁶³ Chemokine signaling pathway ³⁶	13.07	PAK1 NFKBIA NFKB1 JUN CXCL8 CXCL1
17	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²² Thyroid cancer ³⁶	13.04	PTPN11 NFKBIA NFKB1 JUN EGFR CHUK
18	Pathways in cancer ³⁶	13.02	NFKBIA NFKB1 MET JUN IFNGR1 EGFR
19	Herpes simplex virus 1 infection ³⁶	13	PTPN11 NFKBIA NFKB1 IL1B IFNGR1 CHUK
20	Measles ³⁶ Show member pathways Epstein-Barr virus infection ³⁶ Influenza A ³⁶	12.99	NFKBIA NFKB1 JUN IL1B IFNGR1 CXCL8
21	MAPK signaling pathway ³⁶ ¹	12.97	PAK1 NFKB1 MET JUN IL1B EGFR
22	RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways ⁶⁵ Show member pathways Cytosolic DNA-sensing pathway ³⁶ Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²² Negative regulators of RIG-I/MDA5 signaling ⁶⁵ NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 ⁶⁵ RIG-I-like Receptor Signaling ¹ RIG-I-like receptor signaling pathway ³⁶ TRAF3-dependent IRF activation pathway ⁶⁵ TRAF6 mediated IRF7 activation ⁶⁵ Virus Detection and Induction of Antiviral Signaling Pathways by RIG-I-like Receptors (RLR) ⁶⁴	12.92	NFKBIA NFKB1 IL1B CXCL8 CHUK CCL5
23	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ¹ Apoptosis ³⁶ Apoptosis and survival Apoptotic TNF-family pathways ²² Apoptosis Signaling Pathways ⁶⁴ Death Receptor Signaling ⁶⁶	12.91	NFKBIA NFKB1 JUN CHUK CASP3
24	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁵ MET activates STAT3 ⁶⁵ Neurotrophin signaling pathway ³⁶ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.9	PTPN11 PAK1 NFKBIA NFKB1 MET JUN
25	Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁴ Show member pathways Adipokines and Insulin Signaling Pathways ⁶⁴ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁴ IL-2 Signaling Pathways ⁶⁴ IL-21 Signaling Pathways ⁶⁴ IL-4 Signaling Pathways ⁶⁴ IL-7 Signaling Pathways ⁶⁴ IL-9 Pathway ⁶³ IL-9 Signaling Pathways ⁶⁴ Immune response IL-9 signaling pathway ²²	12.89	PTPN11 NFKBIA NFKB1 JUN CHUK
26	Ras signaling pathway ³⁶ Show member pathways Rap1 signaling pathway ³⁶	12.89	PTPN11 PAK1 NFKB1 MET EGFR CHUK
27	Downstream signaling events of B Cell Receptor (BCR) ⁶⁵ Show member pathways Activation of RAS in B cells ⁶⁵ Signaling by the B Cell Receptor (BCR) ⁶⁵	12.88	PTPN11 NFKBIA NFKB1 MET EGFR CHUK
28	4-1BB Pathway ⁶³ Show member pathways CD27 Pathway ⁶³ CD40 Signaling ⁶³ CMV and MAPK Pathways ⁶³ NF-KappaB Activation by EBV ⁶³ NF-kappaB Activation by Viruses ⁶³ PKR Pathway ⁶³ SUMO Pathway ⁶³ TNFR2 Pathway ⁶³	12.87	NFKBIA NFKB1 JUN IL1B IFNGR1 EGFR
29	NF-KappaB Family Pathway ⁶³ Show member pathways NF-KappaB (p50-p65) Pathway ⁶³	12.86	NFKBIA NFKB1 MET IL1B EGFR CHUK
30	Immune response NFAT in immune response ²² Show member pathways Immune response CD28 signaling ²² Immune response ICOS pathway in T-helper cell ²² Immune response T cell receptor signaling pathway ²²	12.8	PAK1 NFKBIA NFKB1 JUN IFNGR1 CHUK
31	DREAM Repression and Dynorphin Expression ⁶³ Show member pathways BMP Pathway ⁶³ Calpain Protease Regulates Cellular Mechanics ⁶³ Caspase Cascade ⁶³ Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels ⁶⁵ nNOS Signaling in Skeletal Muscle ⁶³ TOB in Osteoblast Signaling ⁶³	12.79	PAK1 NFKB1 JUN EGFR CASP3
32	ErbB signaling pathway ¹ ³⁶ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ³⁶ Renal cell carcinoma ³⁶ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.79	PTPN11 PAK1 NFKB1 MET JUN EGFR
33	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶³ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.79	PTPN11 PAK1 NFKBIA NFKB1 IL1B EGFR
34	TRAF Pathway ⁶³ Show member pathways 14-3-3 Induced Apoptosis ⁶³ TNF Superfamily Pathway ⁶³ Toll-Like Receptors Pathway ⁶³	12.78	PAK1 NFKBIA NFKB1 JUN IL1B CHUK
35	Th17 cell differentiation ³⁶ Show member pathways IL-22 Pathway ⁶³ Immune response IL-22 signaling pathway ²² Inflammatory bowel disease (IBD) ³⁶ Th1 and Th2 cell differentiation ³⁶	12.77	NFKBIA NFKB1 JUN IL1B IFNGR1 CHUK
36	NF-kappaB Signaling ⁴	12.74	NOD1 NFKBIA NFKB1 IL1B CHUK CCL5
37	Development ERBB-family signaling ²² Show member pathways Development EGFR signaling pathway ²² EGF Pathway ⁶³ EGFR Signaling Pathway ⁶⁶ ErbB receptor signaling network ¹ GRB7 events in ERBB2 signaling ⁶⁵ PLCG1 events in ERBB2 signaling ⁶⁵	12.73	PAK1 NFKBIA NFKB1 JUN EGFR CHUK
38	Immune response Fc epsilon RI pathway ²² Show member pathways Fc epsilon RI signaling pathway ³⁶ Fc-epsilon receptor I signaling in mast cells ¹ Immune response BCR pathway ²² VEGF signaling pathway ³⁶	12.72	PTPN11 NFKBIA NFKB1 JUN CHUK
39	T cell receptor signaling pathway ³⁶ Show member pathways PD-L1 expression and PD-1 checkpoint pathway in cancer ³⁶ T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.69	PTPN11 PAK1 NFKBIA NFKB1 JUN IL1B
40	Immune response Role of DAP12 receptors in NK cells ²² Show member pathways Immune response CD16 signaling in NK cells ²² Natural killer cell mediated cytotoxicity ³⁶	12.66	PTPN11 PAK1 JUN IFNGR1 CASP3
41	Prolactin Signaling Pathway ¹ ³⁶ Show member pathways Development Prolactin receptor signaling ²² Leptin signaling pathway ¹	12.65	PTPN11 PAK1 NFKBIA NFKB1 JUN IL1B
42	CLEC7A (Dectin-1) signaling ⁶⁵ Show member pathways Alternative NF-kappaB pathway ¹ CLEC7A/inflammasome pathway ⁶⁵ C-type lectin receptors (CLRs) ⁶⁵	12.63	PAK1 NFKBIA NFKB1 MUC6 IL1B CHUK
43	VEGF Pathway (Qiagen) ⁶³ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶³ Development VEGF-family signaling ²² Neurophilin interactions with VEGF and VEGFR ⁶⁵ VEGF Family Ligands and Receptor Interactions ⁶³	12.6	NFKBIA NFKB1 JUN GAST EGFR CHUK
44	Apoptosis Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ NF-kappaB Pathway ⁷⁰	12.6	NFKBIA NFKB1 MET JUN IL1B EGFR
45	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁴	12.59	PTPN11 PAK1 NFKBIA NFKB1 JUN CHUK
46	RANK Signaling in Osteoclasts ⁶³ Show member pathways Apoptosis and survival APRIL and BAFF signaling ²² APRIL Pathway ⁶³ BAFF in B-Cell Signaling ⁶³ RANK Pathway ⁶³ RANKL/RANK (Receptor activator of NFKB (ligand)) Signaling Pathway ¹	12.58	PAK1 NFKBIA NFKB1 JUN CHUK
47	B cell receptor signaling pathway (KEGG) ¹ Show member pathways B cell receptor signaling pathway ³⁶ B Cell Receptor Signaling Pathway ¹	12.57	PTPN11 NFKBIA NFKB1 JUN CHUK
48	RhoGDI Pathway ⁶³ Show member pathways Fc-GammaR-Mediated Phagocytosis in Macrophages ⁶³	12.56	PAK1 MET JUN EGFR CASP3
49	Development IGF-1 receptor signaling ²² Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.56	PTPN11 NFKBIA NFKB1 MET CHUK
50	ICos-ICosL Pathway in T-Helper Cell ⁶³ Show member pathways Calcium Mediated T-Cell Apoptosis ⁶³ CD28 Signaling in T-Helper Cell ⁶³	12.55	PAK1 NFKBIA NFKB1 JUN CHUK

Sources

GO Terms for Helicobacter Pylori Infection

Cellular components related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.65	S100A8 NFKB1 MUC6 MET IL1B GAST
2	I-kappaB/NF-kappaB complex	GO:0033256	8.62	NFKBIA NFKB1

Biological processes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show all 43)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.25	NOD1 NFKB1 MET IL1B IFNGR1 GAST
2	positive regulation of transcription by RNA polymerase II	GO:0045944	10.2	NFKBIA NFKB1 MET JUN IL1B EGFR
3	positive regulation of transcription, DNA-templated	GO:0045893	10.09	NFKBIA NFKB1 JUN IL1B EGFR CHUK
4	immune response	GO:0006955	10.07	IL1B CXCL8 CXCL1 CHUK CCL5
5	intracellular signal transduction	GO:0035556	10.06	NOD1 EGFR CXCL8 CXCL1 CASP3
6	apoptotic process	GO:0006915	10.04	S100A8 PAK1 NOD1 NFKBIA NFKB1 IL1B
7	MAPK cascade	GO:0000165	9.97	PAK1 MET IL1B EGFR CCL5
8	positive regulation of cell migration	GO:0030335	9.97	PAK1 IL1B EGFR CCL5 ADAM10
9	cellular response to lipopolysaccharide	GO:0071222	9.93	NFKB1 IL1B CXCL8 CXCL1
10	Fc-epsilon receptor signaling pathway	GO:0038095	9.93	PAK1 NFKB1 JUN CHUK
11	chemotaxis	GO:0006935	9.92	S100A8 CXCL8 CXCL1 CCL5
12	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.91	PTPN11 NOD1 JUN EGFR CCL5
13	stimulatory C-type lectin receptor signaling pathway	GO:0002223	9.88	PAK1 NFKB1 MUC6 CHUK
14	cellular response to interleukin-1	GO:0071347	9.86	NFKB1 CXCL8 CCL5
15	wound healing	GO:0042060	9.86	S100A8 PAK1 EGFR CASP3
16	liver development	GO:0001889	9.85	MET JUN EGFR
17	positive regulation of cell growth	GO:0030307	9.85	S100A8 EGFR ADAM10
18	chemokine-mediated signaling pathway	GO:0070098	9.85	CXCL8 CXCL1 CCL5
19	cellular response to organic cyclic compound	GO:0071407	9.84	IL1B CCL5 CASP3
20	response to organic substance	GO:0010033	9.84	PAK1 JUN CHUK CASP3
21	I-kappaB kinase/NF-kappaB signaling	GO:0007249	9.83	NFKBIA NFKB1 CHUK
22	positive regulation of NIK/NF-kappaB signaling	GO:1901224	9.83	NOD1 IL1B EGFR
23	positive regulation of inflammatory response	GO:0050729	9.83	S100A8 NFKBIA IL1B EGFR
24	positive regulation of interleukin-6 production	GO:0032755	9.82	PTPN11 NOD1 IL1B
25	positive regulation of smooth muscle cell proliferation	GO:0048661	9.82	JUN EGFR CCL5
26	response to cytokine	GO:0034097	9.81	NFKB1 JUN CCL5
27	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.8	S100A8 NOD1 NFKB1 IL1B CHUK
28	cellular response to reactive oxygen species	GO:0034614	9.79	JUN EGFR CHUK
29	cellular response to cadmium ion	GO:0071276	9.78	JUN EGFR CHUK
30	cellular response to mechanical stimulus	GO:0071260	9.78	PTPN11 NFKB1 IL1B EGFR
31	response to tumor necrosis factor	GO:0034612	9.77	CCL5 CASP3 ADAM10
32	lipopolysaccharide-mediated signaling pathway	GO:0031663	9.77	NFKBIA IL1B CCL5
33	cellular response to tumor necrosis factor	GO:0071356	9.77	NFKBIA NFKB1 CXCL8 CHUK CCL5
34	interleukin-1-mediated signaling pathway	GO:0070498	9.72	NOD1 NFKBIA NFKB1 IL1B CHUK
35	hepatocyte growth factor receptor signaling pathway	GO:0048012	9.69	PAK1 MET
36	negative regulation by host of viral transcription	GO:0043922	9.69	JUN CCL5
37	neutrophil activation	GO:0042119	9.68	CXCL8 CCL5
38	neutrophil chemotaxis	GO:0030593	9.65	S100A8 IL1B CXCL8 CXCL1 CCL5
39	astrocyte activation	GO:0048143	9.63	IL1B IFNGR1 EGFR
40	response to lipopolysaccharide	GO:0032496	9.63	S100A8 NFKBIA JUN IL1B CHUK CASP3
41	response to muscle stretch	GO:0035994	9.61	NFKBIA NFKB1 JUN
42	cytokine-mediated signaling pathway	GO:0019221	9.5	PTPN11 IL1B IFNGR1 CXCL8 CXCL1 CCL5
43	inflammatory response	GO:0006954	9.23	S100A8 NOD1 NFKB1 IL1B CXCL8 CXCL1

Molecular functions related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein homodimerization activity	GO:0042803	9.8	NOD1 NFKB1 JUN CHUK CCL5 ADAM10
2	identical protein binding	GO:0042802	9.7	NOD1 NFKBIA NFKB1 MET JUN EGFR
3	protein binding	GO:0005515	9.58	S100A8 PTPN11 PAK1 NOD1 NFKBIA NFKB1
4	cytokine activity	GO:0005125	9.56	IL1B CXCL8 CXCL1 CCL5
5	chemokine activity	GO:0008009	9.13	CXCL8 CXCL1 CCL5

Sources

Sources for Helicobacter Pylori Infection

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia